AUTHORS
Sabrina Giammarco, MD, Andrea Bacigalupo, MD2, Dirk-Jan Eikema3, Anna Maria Raiola, MD4, Beatrice Drexler, MD5, Francis Ayuk6, Nour Ben Abdeljelil, MD7, Khalid Halahleh, MD8, Catherine Flynn9, Alexander Kulagin10, Juan Montoro11, Robert Zeiser, MD, PhD12, Mohsen Alzahrani Sr, MD13, Hélène M Schoemans, MD, PhD14, Wolfgang Bethge, MD15, Arancha Bermúdez, MD16, Pavel Jindra, PhD17, Hakan Ozdogu, MD18, Ludek Raida19, Ipek Yonal Hindilerden, MD20, Martin Kaufmann, MD21, Peter Svec Sr, MD, PhD22, Brian Piepenbroek23, Joe Tuffnell24, Carlo Dufour I, MD25, Regis Peffault De Latour, MD, PhD26, Flore Sicre-de-Fontbrune, MD27, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP28, Antonio M. Risitano Jr, MD, PhD29
AFFILIATIONS
1 Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Lazio, Italy
2 Università Cattolica del Sacro Cuore, Roma, Italy
3 EBMT Leiden Study Unit, Leiden, Netherlands
4 AOM – IRCCS Ospedale Policlinico San Martino. UO Ematologia e Terapie Cellulari, Genova, Liguria, Italy
5 University Hospital | Basel, Basel, Switzerland
6 University Hospital Eppendorf, Hamburg, Germany
7 CNGMO-Centre National de Greffe de la Moelle Osseuse, Tunis, Tunis, Tunisia
8 King Hussein Cancer Centre Adult BMT Program, Amman, Jordan
9 Hope Directorate - St. James's Hospital, Dublin, Ireland
10 RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation
11 University Hospital La Fe, Valencia, Spain
12 University of Freiburg, Freiburg, Germany
13 King Abdul - Aziz Medical City, Riyadh, Saudi Arabia
14 University Hospitals Leuven and Department of Public Health and Primary Care, ACCENT VV, KU Leuven, Leuven, Belgium
15 Universitaet Tuebingen, Tübingen, Germany
16 Hospital U. Marques de Valdecilla, Santander, Spain
17 Charles University Hospital, Pilzen, Czech Republic
18 Baskent University Hospital, Adana, Turkey
19 Olomouc University Hospital, Olomouc, Czech Republic
20 Istanbul University Faculty of Medicine, Instanbul, Turkey
21 Robert Bosch Krankenhaus, Stuttgart, Germany
22 National Institute of Children's Diseases, Bratislava, Slovakia
23 EBMT Leiden Study Unit, Leiden, Netherlands
24 EBMT Leiden Study Unit, Leiden, Netherlands
25 Institute G. Gaslini, Genova, Italy
26 Saint-Louis Hospital, BMT Unit, Paris, France
27 Saint-Louis Hospital, BMT Unit, Paris, France
28 Kings College Hospital, London, United Kingdom
29 A.O.R.N. 'SAN.G MOSCATI', Avellino, Italy
ABSTRACT
Introduction
Fertility preservation can be major concern in young women undergoing allogeneic HSCT for acquired severe aplastic anemia (SAA). The high risk of primary or secondary graft failure, which is typical of SAA, has induced several centers to use total body irradiation (TBI) in the conditioning (Int J Radiat Oncol Biol Phys.1988;14:1133-41) as a means to ensure strong engraftment. A TBI dose greater than 8 Gy, has been shown to affect fertility (Blood. 2024;144:1532-1542), and the question is whether this is true also for a TBI dose of 2Gy, since a rather common conditioning regimen for AA patients undergoing UD HSCT includes fludarabine and cyclophosphamide, followed by TBI 2Gy (FluCy TBI) (Haematologica.2010;95:976-82). We therefore designed a retrospective study, with the primary aim of assessing whether females have reduced fertility after conditioning with FluCy TBI 2Gy, as compared to Cy 200 or Flu-Cy.
Methods: Data were derived from the Severe Aplastic Anaemia Working Party (SAAWP) of the EBMT. Eligible for the study were females aged 18-40 at time of HSCT, allografted between 1980 and 2020, receiving Cy200, FluCy, or FluCy TBI 2Gy conditioning, and alive in follow-up 6 months after an allogeneic HSCT. The primary outcome was the cumulative incidence (CI) of first documented pregnancy from HSCT, with death as the competing event. Group differences are evaluated with Gray’s test. Cox regression was used to evaluate the effect of conditioning, age and cGvHD on pregnancy, where cGvHD was included as a time dependent covariate.
Patients. A total of 746 females participated in the study, receiving Cy 200 (n=453); FluCy (n=169) and FluCy TBI 2Gy (n=124), with comparable median ages of 25.4 yrs (21-31), 25.1 (21-31) and 26.2 yrs (21-31) respectively (p=ns). There was an increased use of alternative donors in the FluCy (39%) and FluCy TBI group (88%), compared with Cy200 (7%) (p<0.001).
Patients in the FluCy group had higher performance score (80% had 90-100), versus 72% and 73% in Cy200 and FluCy TBI (p=0.03) and were less likely to receive a BM graft (62% versus 71% and 69%) (p<0.001). Patients receiving Cy200 were less likely to have a male donor (54%, versus 62% with FluCy and 64% with FluCy TBI) or In vivo T-cell depletion (73% versus 77% and 79%) (p<0.01). The 10-year CI of cGvHD was 15%, with no significant difference in the three groups (p=0.13).
Results. The 10-year overall survival for the population is 91% (88-93%), with no statistically significant differences in the three groups. During follow-up, 168 females (22%) became pregnant. The median time between the HCT and first pregnancy was 4.4 years (IQR 2.6-7.5), with the median time to first delivery 5.6 (IQR 3.2, 8.7) yrs. The median time to first pregnancy was 4.8 yrs for Cy-200, 3.5 yrs for FluCy and 4 yrs for FluCy TBI.
The 10-year overall CI of pregnancy was 34% (29-39%), comparable between Cy200 (33% (27%-39%)) and FluCy TBI (32% (18-46%)), and non-significantly higher in the FluCy (41% (29%-53%), p=0.39).
In a Cox analysis on the probability of becoming pregnant, chronic GvHD during follow-up had a strong negative effect on the pregnancy rate (HR=0.63 (0.41-0.97), p=0.036), together with increasing patient age (HR=0.92 (0.9-0.95) for each 1 year increase (p<0.001); there was no statistically significant difference between Cy200 and FluCy (HR=1.39 (0.94-2.05), p=0.1), or FluCy TBI (HR=0.98 (0.6-1.61), p=0.9).
Conclusions
In this large registry analysis, we confirm that the most common conditioning regimens used for HSCT in SAA may all preserve fertility. Indeed, Flu-Cy-TBI2 Gy resulted in a likelihood of pregnancy comparable with that of Cy 200, and not statistically different from that of Flu-Cy without TBI.Conversely, in addition to older age, chronic GvHD was associated with a lower pregnancy rate, identifying this as a potentially actionable target to preserve fertility after HCT.
DISCLOSURES
Sabrina Giammarco, MD: No relevant conflicts of interest to declare.